Abbott Laboratories
ABT Healthcare Medical - Devices NYSE
$109.77
$-1.27 (-1.14%)
Open: $110.72 | High: $110.72 | Low: $108.34 | Prev Close: $111.04
Market Cap: $190.75B
Volume: 8.3M | Avg: 9.2M
Last updated: March 09, 2026 at 02:00 AMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 565
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 29.51 |
| P/B Ratio | 3.68 |
| P/S Ratio | 4.30 |
| EPS | $3.72 |
| Beta | 0.74 |
| Shares Outstanding | 1.74B |
| 52-Week High | $139.15 |
| 52-Week Low | $105.27 |
| SMA 50 | $116.70 |
| SMA 200 | $127.00 |
| Dividend Yield | 2.19% |
| Annual Dividend | $2.40 |
| Next Earnings | April 15, 2026 01:30 PM ET |
Financial Ratios
| Gross Margin | 55.5% |
| Operating Margin | 18.2% |
| Net Margin | 14.7% |
| ROE | 12.9% |
| ROA | 7.5% |
| Debt/Equity | 0.29 |
| Current Ratio | 1.58 |
| Quick Ratio | 1.18 |
Balance Sheet
| Total Assets | $86.71B |
| Total Liabilities | $33.94B |
| Total Equity | $52.13B |
|
|
|
| Cash | $8.52B |
| Total Debt | $15.07B |
| Net Debt | $6.54B |
Income Statement
| Revenue | $44.33B |
| Gross Profit | $24.61B |
| Operating Income | $8.05B |
| Net Income | $6.52B |
|
|
|
| EBITDA | $11.55B |
| Revenue/Share | $25.37 |
Cash Flow
| Operating CF | $9.57B |
| CapEx | $2.17B |
| Free Cash Flow | $7.39B |
|
|
|
| Book Value/Share | $30.21 |
| Tangible Book/Share | $13.29 |
| Equity/Share | $29.84 |
Technical Indicators
| RSI (14) | 39.65 Neutral |
| MACD |
-0.68
Signal: -0.68
|
| Volatility | 19.61% |
| Trading Signal | Neutral |
Performance & Returns
| 1 Year | -19.02% |
| Sharpe Ratio | -1.24 Poor |
| Volatility (Ann.) | 22.89% Moderate |
| ABT (1Y) | -19.02% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | -32.05% |
Sector Comparison (Healthcare)
| Metric | ABT | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 29.51 | 27.62 | 59% |
| P/B Ratio | 3.68 | -19.59 | 60% |
| ROE (%) | 12.89% | -9.53% | 51% |
| Net Margin (%) | 14.72% | 9.21% | 64% |
| Stock Score | 565 | 543.0 | 59% |
| 1Y Return (%) | -19.02 % | +8.68 % | 15% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABT | $109.77 | $112.30 | $113.54 | $113.36 | $116.24 | $126.83 | 39.65 | -0.68 | 19.61% | 1318954 | Weak Short | Price Below SMAs |
Candlestick Patterns
There wasn't any recognizable pattern for the ABT stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| ABT | Pivot Bio CEO Chris Abbott to Present at World Agri-Tech Innovation Summit | Neutral | businesswire.com | Read More |
| ABT | Invesco Rising Dividends Fund Q4 2025 Portfolio Activity | Neutral | seekingalpha.com | Read More |
| ABT | Absolute Software Co. (ABT.TO) (TSE:ABT) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s Why | Neutral | defenseworld.net | Read More |
| ABT | Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management | Neutral | prnewswire.com | Read More |
| ABT | Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team' | Neutral | prnewswire.com | Read More |
Recent Insider Trading
No recent insider trading data available for ABT
Company Information
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
| CEO | Robert Ford |
| Employees | 114000 |
| Country | US |
| IPO Date | 1980-03-17 |
| Exchange | NYSE |
| Website | https://www.abbott.com |
| Sector | Healthcare |
| Industry | Medical - Devices |
Similar Stocks (Healthcare - Medical - Devices)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category